

# **Investigating the effects of ABL kinase inhibitors on the signalling and function of normal leukocytes and leukemic cells**

**Stephen Blake**

Melissa White Leukaemia Research Laboratory  
Department of Haematology  
Hanson Institute  
Institute of Medical and Veterinary Science

&

Department of Microbiology and Immunology  
School of Biomedical Science  
University of Adelaide

A thesis submitted to the University of Adelaide in  
Candidature for the Degree of Doctor of Philosophy

19<sup>th</sup> December 2008, Resubmitted June 2009



2.2.11.	Thaw Media .....	27
2.2.12.	ELISA development buffers .....	27
2.2.12.1.	0.1 M Citric Acid solution .....	27
2.2.12.2.	0.2M Dibasic sodium phosphate solution.....	27
2.2.12.3.	Phospho Citrate buffer .....	27
2.2.12.4.	TMB ELISA development Buffer .....	28
2.2.13.	Tyrosine kinase inhibitors.....	28
2.2.13.1.	Dasatinib (10 mg/ml stock).....	28
2.2.13.2.	Imatinib (10 mM stock) .....	28
2.2.13.3.	Nilotinib (10 mM stock) .....	28
2.2.14.	White Cell Fluid (WCF) .....	29
2.3.	Cell culture Techniques .....	29
2.3.1.	Maintenance of cell lines.....	29
2.3.2.	Washing Cells.....	30
2.3.3.	Isolation of mononuclear cells (MNCs) .....	30
2.3.4.	Freezing cells.....	30
2.3.5.	Thawing cells.....	31
2.3.6.	Cell counting .....	31
2.3.7.	Isolation of human T-cells.....	31
2.3.8.	Isolation of human Natural killer (NK) cells.....	32
2.3.9.	Intracellular flow cytometry .....	33
2.3.9.1.	Fixation and permeabilization of cells for flow signalling.....	33
2.3.9.2.	Fixation of cells for cell cycle analysis.....	33
2.3.9.3.	Antibodies used for intracellular flow cytometry .....	33
2.3.9.4.	Flow signalling .....	34
2.3.9.5.	Cell cycle analysis .....	35
2.3.10.	Other flow cytometry protocols.....	35
2.3.10.1.	Antibodies used for surface staining of cells.....	35
2.3.10.2.	Cell surface staining with antibodies.....	36
2.3.10.3.	CFSE labelling cells.....	37
2.3.10.4.	Tracking cell division using CFSE staining .....	37
2.3.10.5.	Calculation of proliferation index (PI).....	37
2.3.10.6.	Analysing cell viability by flow cytometry .....	38
2.3.10.7.	Counting cells .....	39
2.3.10.8.	Natural killer cell cytotoxicity assays.....	39
2.3.10.9.	T-cell proliferation assays.....	40
2.3.11.	ELISA to detect IFN- $\gamma$ .....	40
2.4.	Reagents for molecular biology techniques.....	41
2.4.1.	10% SDS solution .....	41
2.4.2.	10X SDS-PAGE buffer .....	41
2.4.3.	1X SDS-PAGE running buffer.....	42
2.4.4.	1X Membrane Transfer buffer.....	42
2.4.5.	10X TBS .....	42
2.4.6.	TBS washing buffer.....	42
2.4.7.	TBS-T washing buffer.....	43
2.4.8.	Laemmli's buffer for cell lysis and protein stabilisation.....	43
2.4.9.	2X SDS loading dye .....	43
2.4.10.	NP-40 lysis buffer .....	44
2.4.11.	NP-40 lysis buffer with protease inhibitors .....	44
2.4.12.	SDS page gel preparation .....	45
2.4.12.1.	Buffer A (1.5 M Tris pH 8.8) for resolving gel .....	45
2.4.12.2.	Buffer B (0.5 M Tris pH 6.8) for stacking gel.....	45
2.4.12.3.	APS solution .....	45

2.4.12.4.	Resolving gel preparation (7.5% acrylamide) for 2 gels .....	45
2.4.12.5.	Stacking gel preparation (5% acrylamide) for 2 gels .....	46
2.4.13.	4X Kinase buffer .....	46
2.4.14.	Western Block solution .....	47
2.4.15.	Western Strip solution .....	47
2.5.	Molecular Biology techniques .....	47
2.5.1.	Whole cell lysate preparation .....	47
2.5.2.	Immunoprecipitation of Zap70 .....	48
2.5.3.	Protein separation using SDS-PAGE gel electrophoresis .....	48
2.5.4.	Transfer of protein from SDS-PAGE gel to PVDF membrane .....	49
2.5.5.	Immuno probing western blot membranes .....	49
2.5.5.1.	Antibodies used for western blotting .....	49
2.5.5.2.	Washing blots .....	50
2.5.5.3.	Probing blots using phospho-specific antibodies .....	51
2.5.5.4.	Probing blots using total protein antibodies .....	51
2.5.5.5.	Detection of antibody signal on western blots .....	51
2.5.5.6.	Stripping western blots of antibodies .....	51
2.5.5.7.	Quantitation of protein phosphorylation .....	52
2.5.6.	LCK kinase assay .....	52
2.6.	Statistical analysis .....	53
3.	Evaluating BCR/ABL signalling pathways using flow cytometry .....	54
3.1.	Introduction .....	55
3.1.1.	Activation of the stat5 pathway by BCR/ABL .....	56
3.1.2.	Effects of BCR/ABL on the MAPK pathway .....	56
3.1.3.	Effects of BCR/ABL on the PI3 Kinase pathway .....	56
3.2.	Results .....	59
3.2.1.	Analysis of a panel of anti-phosphoprotein antibodies .....	59
3.2.1.1.	Development of standard method for phospho flow cytometry .....	59
3.2.1.2.	Detection of phosphorylated Stat5 .....	60
3.2.1.3.	Phosphorylation in the Ras/Raf MAPK signalling pathway .....	61
3.2.1.4.	Phosphorylation via the PI3 kinase pathway .....	61
3.2.2.	Adaptation of the assay for analysis of primary CML cells .....	62
3.2.2.1.	Detection of stat5 phosphorylation CML and normal cells .....	62
3.2.2.2.	Detection of P-ERK and p-AKT in CML and normal MNCs .....	63
3.2.2.3.	Response of CML cells to stimulation with GM-CSF .....	64
3.2.2.4.	Analysis of blood MNCs from the panel of CML patients by phospho-flow cytometry .....	65
3.2.3.	Heterogeneous responses of CD34 <sup>+</sup> cells from CML patients to culture with imatinib .....	65
3.2.3.1.	Correlation between initial phospho-protein levels and sensitivity of patient MNCs to inhibition of BCR/ABL by imatinib .....	66
3.2.3.2.	Comparison between samples from patients during blast crisis .....	68
3.3.	Discussion .....	69
4.	Dasatinib inhibits the function of normal human T-lymphocytes .....	74
4.1.	Introduction .....	75
4.2.	Results .....	78
4.2.1.	Determining optimal CFSE staining conditions .....	78
4.2.2.	Dasatinib inhibits polyclonal T-cell proliferation in response to polyclonal stimuli .....	79
4.2.2.1.	Dasatinib inhibits proliferation of both CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cells .....	80
4.2.2.2.	Dasatinib blocks antigen specific T-cell proliferation .....	80
4.2.2.3.	Dasatinib can inhibit actively dividing T-cells and the effects are reversible .....	81

4.2.2.4.	Dasatinib blocks T-cell division by reducing the number of cells entering cell cycle, not by reducing degree of proliferation in dividing cells...	82
4.2.3.	Dasatinib blocks stimulated T-cells from entering cell cycle .....	83
4.2.4.	Dasatinib blocked early activation events in T-cells.....	84
4.2.5.	Dasatinib blocks T-cell production of inflammatory cytokine IFN- $\gamma$ .....	85
4.2.6.	Viability of T-cells was not reduced by dasatinib.....	85
4.2.7.	Protein phosphorylation is reduced in normal human T-cells in the presence of dasatinib .....	86
4.2.7.1.	Dasatinib interrupts early signalling events downstream of the TCR .	
	.....	87
4.2.7.2.	Dasatinib blocks downstream TCR signalling.....	87
4.3.	Discussion.....	89
5.	The small molecule tyrosine kinase inhibitor nilotinib inhibits T-cell function in a similar manner to the structurally related imatinib.....	94
5.1.	Introduction.....	95
5.2.	Results.....	97
5.2.1.	Nilotinib inhibits LCK phosphorylation following TCR stimulation .....	97
5.2.2.	Nilotinib blocks LCK kinase activity.....	97
5.2.3.	Nilotinib inhibits T-cell proliferation .....	98
5.2.3.1.	Nilotinib blocks polyclonal T-cell proliferation .....	98
5.2.3.2.	Antigen specific T-cell proliferation is inhibited by nilotinib .....	99
5.2.3.3.	The effects of nilotinib on T-cell proliferation are reversible .....	100
5.2.4.	Nilotinib inhibits T-cell activation marker expression.....	101
5.2.5.	Nilotinib inhibits T-cell cytokine production.....	101
5.2.6.	Nilotinib does not affect T-cell viability .....	102
5.3.	Discussion.....	104
6.	Investigation of synergy between tyrosine kinase inhibitors and cyclosporine for inhibition of T-cell proliferation.....	108
6.1.	Introduction.....	109
6.2.	Results.....	112
6.2.1.	CFSE dye dilution assay to measure inhibition of T-cell proliferation by drug combinations .....	112
6.2.2.	Statistical analysis of drug interactions .....	112
6.2.3.	Determining interactions between dasatinib and cyclosporine .....	113
6.2.4.	Proliferation induced by anti-CD3/CD28 microbeads in both CD4 <sup>+</sup> and CD8 <sup>+</sup> T-cell is enhanced by the combination of dasatinib plus cyclosporine A .....	114
6.2.5.	Determining interactions between imatinib and cyclosporine .....	115
6.2.6.	Investigation of alternative methods for analysing drug interactions ...	116
6.2.6.1.	Use of responder frequency to determine CI values.....	116
6.2.6.2.	Use of fixed drug ratios .....	117
6.2.7.	Re-analysis of interactions between dasatinib and CsA using a 1:1 fixed drug ratio .....	118
6.3.	Discussion.....	120
7.	Dasatinib Inhibits Natural Killer Cell Cytotoxicity .....	127
7.1.	Introduction.....	128
7.2.	Results.....	131
7.2.1.	Isolation and identification of NK cells.....	131
7.2.2.	Characterising NK cytotoxicity against target cells, using flow cytometry .....	131
7.2.3.	Dasatinib inhibits NK cell cytotoxicity against K562 and Jurkat cell lines .....	132
7.2.4.	The effects of dasatinib on NK cytotoxicity were reversible.....	133
7.2.5.	Imatinib had only a minor impact on NK cell cytotoxicity.....	134

7.3. Discussion.....	135
8. General discussion.....	138
8.1. General discussion.....	139
9. References.....	148
9.1. References.....	149
APPENDIX.....	166

# Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

Stephen Blake

# Acknowledgements

Where to begin on thanking the many, many people who have helped me over the course of my PhD, without your assistance and support my “postgraduate journey” would have been near impossible.

Firstly I would like to thank my supervisors; Dr. Bruce Lyons, Prof. Tim Hughes and Prof. Graham Mayrhofer. I would particularly like to thank Bruce for his continued support and interest in my project during his relocation to Flinders University and then Tasmania. Without your ideas and suggestions I doubt my project would have taken the path it did or be near as successful. Many thanks as well to Prof. Tim Hughes for allowing me to perform my PhD in your laboratory and for your ideas and ongoing support over the years. I would also like to thank Graham for his suggestions and ideas for my project, and for going over all my written work with a fine toothed comb.

I would like to thank all the past and present members of the Melissa White Laboratory for all their willing help over the years. I would particularly like to thank Verity Saunders for her enormous help in the lab and for not complaining when she printed me a protocol for the n<sup>th</sup> time and Dr. Deb White for her ideas and input into my project. I am sure all other MWL members have also helped over the years; Laura Eadie, Phuong Dang, Amity Frede and Kelvin Grootobbink, Lisa Schafranek, Sasha Wheeler, Stephanie Arbon and Bron Cambareri. I also would like to thank previous MWL members; Dr. Sarah Swinburne and Stephanie Zrim who left during my candidature.

The regular contact with fellow PhD students was a major influence on my project. The other students in the MWL; Dr. Devendra Hiwase, Dr. David Ross, Carine Tang and Jane Engler have all been fantastic to work with in the lab. The fact you all were willing to discuss controversial results or listen to me vent when things were not going so smoothly was a great help during difficult times. I would also like to thank Dr. Ponghtep Viboonjuntra who completed his PhD in the MWL early during my candidature but was a huge help when I was starting out in the lab. It has also been great working alongside students from other labs including; Emma Gordon, Kelly Betterman and Jantina Manning just to name a few.

There are a number of other researchers within the IMVS and Adelaide University that have assisted me with my study and experiments. The collaboration set up with Cara Frazer and Dr. John Hayball of the Samson Institute has been very productive and both have been fantastic people to work with and bounce ideas off. I would also like to thank Dr. Mark Guthridge, Dr. Jason Powell and Dr. Daniel Thomas of the Cell Growth and Differentiation Laboratory for all their help with Western blotting and kinase assays in my thesis. Without your patient assistance and expertise, these difficult experiments would not have been near as successful. I would also like to thank the members of the Detmold Imaging facility; Alan Bishop, Sandy McIntyre, Kate Pilkington and Ghafar Sarvestani who have given me tremendous assistance in the many hours I have spent on flow cytometers. I would also like to thank the Australian Red Cross Service for giving me all the Buffy coat samples I required for my research. I also would like to thank Tony Cambareri for all his help with general lab and computer problems. I would also like to thank Duncan Hewett of the Melo Lab for all the uncredited proof-reading he has done for me over the years and for always being up for a morning coffee to discuss recent lab and sporting results.

I have to mention all my family who have given me so much support over the last 3 ½ years. To my mum, thank you so much for your love and support during my studies, I have often thought you have been more interested and excited by my PhD than I have! To my sisters Laura and Bec, thanks so much for your support and for putting up with me when I was in a mood. And thanks to my friends who have been very supportive and given me an outlet from science, especially those who have put up with my bad guitar playing.

Finally I must thanks to the Professor Bik To for allowing me conduct my PhD within the Division of Haematology within the IMVS, and for Adelaide University, School of Biomedical Sciences, Department of Microbiology and Immunology for allowing me enrol through their school and for the financial support.

# Abstract

Specifically targeting the oncogenic proteins that cause cancers is a rapidly growing field of laboratory and clinical research. The paradigm of this field is the tyrosine kinase inhibitor imatinib, which specifically targets chronic myeloid leukaemia (CML) by inhibiting the kinase activity of the BCR/ABL oncogene. Whilst highly successful for the treatment of CML, 10-20% of patients are resistant to imatinib and require an alternative treatment. Identification of the poor responding patients is important and many different methods have been used to determine patient prognosis. In this study, flow cytometric detection of protein phosphorylation was tested as a method to determine patient prognosis and stat5 was identified as a useful marker in CML. Although only a small group of patients was analysed, there appeared to be a correlation between the percentage of cells with detectable p-stat5 and cellular response to imatinib.

A need for alternative therapies for patients failing imatinib has led to the development of more potent second generation ABL kinase inhibitors. The currently approved second generation inhibitors nilotinib and dasatinib are respectively around 20 and 300 times more potent at inhibiting ABL than imatinib. While imatinib blocks ABL kinase activity, it also inhibits several other kinases including LCK, a Src-family kinase involved in T-cell development and activation. Imatinib has been shown to affect the function of normal T-cells *in vitro* and *in vivo*, likely through inhibition of LCK and thus, the impact of the more potent second generation ABL inhibitors on T-cell function was tested. Nilotinib was found to inhibit T-cell function *in vitro*, affecting T-cell proliferation activation and cytokine production approximately twice as potently as imatinib. Like imatinib, nilotinib also blocked LCK kinase activity with an IC50 of

550 nM, half the IC<sub>50</sub> for imatinib that was approximately 1250 nM. Dasatinib has previously been shown to potently inhibit LCK with an IC<sub>50</sub> of 1.1 nM, and accordingly was shown to strongly inhibit all T-cell functions tested *in vitro*. Dasatinib was also shown to inhibit natural killer cytotoxicity at a similar potency to T-cells, most likely through inhibition of Src-family kinases LCK and FYN.

While T-cell suppression is a potential side effect during cancer therapy, it suggests ABL kinase inhibitors may be a useful for treating diseases involving T-cells such as rheumatoid arthritis. To examine their potential to add to conventional T-cell suppressive regimes, T-cell proliferation in the presence of kinase inhibitors in combination with a standard immuno-suppressive drug cyclosporine. This was performed using a novel flow cytometry based method utilizing CFSE dye to detect cell proliferation. Using this method, both dasatinib and imatinib were shown to act in synergy with cyclosporine to block T-cell proliferation for most stimuli. However, following stimulation with anti-CD3/CD28 microbeads the interaction between dasatinib and cyclosporine was found to be strongly antagonistic. Overall this study has characterised the off-target effects of nilotinib and dasatinib on immune cell functions, and developed a new flow cyometric method which can be used to determine interactions between any drugs that inhibit cell proliferation.

# Abbreviations

7AAD	7-aminoactinomycinD
ABL	Abelson kinase
AKI	ABL kinase inhibitor
ALL	Acute lymphoblastic leukaemia
AML	Acute myeloid leukaemia
AP	Accelerated phase
ATP	Adenosine triphosphate
BC	Blast crisis
BCR	Breakpoint cluster region
BM	Bone marrow
bp	Base pairs
BSA	Bovine serum albumin
C	Celcius
cDNA	Complementary deoxyribonucleic acid
CFSE	5-6-carboxyfluorescein diacetate, succinimidyl ester
CI	Combination index
CML	Chronic myeloid leukaemia
ConA	Concanavalin A
CP	Chronic phase
CPM	Counts per minute
CsA	Cyclosporine A
DMSO	Dimethyl sulphoxide
DNA	Deoxyribonucleic acid
EDTA	Ethylene diamine tetraacetate

ELISA	Enzyme linked immunosorbent assay
FACS	Fluorescence activated cell sorting
FITC	Fluorescein isothiocyanate
FCS	Foetal calf serum
G-CSF	Granulocyte colony stimulating factor
GM-CSF	Granulocyte monocyte colony stimulating factor
Grb2	Growth factor receptor bound Protein 2
HBSS	Hanks Balanced Salt Solution
HLA	Human leukocyte antigen
HRP	Horseradish peroxidase
IC50	50% inhibitory concentration
IFN- $\alpha$	Interferon alpha
IFN- $\gamma$	Interferon gamma
IL-3	Interleukin-3
JAK	Janus Kinase
kD	Kilo Dalton
L	Litre
LCK	Leukocyte specific protein tyrosine kinase
LFU	Lytic formic unit
M	Molar
mA	Milli Amp ( $10^{-3}$ Amp)
MACS	Magnetically activated cell sorting
MAPK	Mitogen activated protein kinase
MFI	Mean fluorescence intensity
mM	milli Molar ( $10^{-3}$ Molar)
MNC	Mononuclear cells

mRNA	Messenger ribonucleic acid
$\mu\text{M}$	Micro Molar ( $10^{-6}$ Molar)
$\mu\text{g}$	Micro gram ( $10^{-6}$ gram)
ND	Not done
NK	Natural killer
NS	Non-stimulated
ng	Nano gram ( $10^{-9}$ gram)
PBMC	Peripheral blood mononuclear cell
PBA	PBS with BSA
PBS	Phosphate Buffered Saline
PBS-T	PBS with Tween 20®
PCR	Polymerase chain reaction
PE	Phycoerythrin
Pg	Pico gram ( $10^{-12}$ gram)
PFA	Paraformaldehyde
Ph	Philadelphia chromosome
PHA	Phytohaemagglutinin
Phe	Phenylalanine
PI	proliferation index
PI3-K	Phosphatidylinositol – 3-kinase
PKA	cAMP- dependent protein kinase
PVDF	Polyvinylidene Fluoride
RCF	Relative centrifugal force
RF	Responder frequency
RNA	Ribonucleic acid
RPM	Revolutions per minute

RPMI	Roswell Park Memorial Institute (media)
RO	Reverse osmosis
RQ-PCR	Reverse transcription quantitative polymerase chain reaction
RT	Room temperature
RT-PCR	Reverse transcription polymerase chain reaction
SD	Standard deviation
SDS	Sodium Dodecyl Sulphate
SDS-PAGE	Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
SFK	Src-family tyrosine kinase
TEMED	1,2-bis(dimethylamino)- ethane
TKI	Tyrosine kinase inhibitor
Tyr	Tyrosine
UV	Ultraviolet
v/v	Volume per volume
WCC	White cell count
WCF	White cell fluid
w/v	Weight per unit volume

# Publications

1. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. *Blood*. 2008 Apr 15;111(8):4415-6.
2. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS 354825) inhibits function of normal human T-lymphocytes in vitro. *Clin Immunol*. 2008 June;127(3):330-9.
3. Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. *J Cellular Mol Med*, Mar;13(3):599-601.
4. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T cell responses and NK cell cytolytic activity in vitro and in vivo, *Experimental Haematology*, 2009 Feb;37(2):256-265.